1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Krka Targets Sales Growth Under New Five-Year Plan – With EBITDA Margin To Regress

Slovenian Firm Wants More Vertical Integration, Boosts Activity In China

 
• By Dean Rudge

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

strategy concept - hands holding back-lit blue puzzle pieces coming together
• Source: Shutterstock

Growing sales volumes and value by at least 5%, averaging an EBITDA margin of at least 25%, and strengthening the company’s vertically integrated business model are among the strategic objectives laid out by Slovenian firm Krka under a new five-year business plan extending to 2028.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

 
• By Adam Zamecnik

The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.